Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Sarcoidosis: Insights into the Targets of Cellular Immunity

Lara C. Pullen, PhD  |  March 6, 2017

Both rheumatoid arthritis and sarcoidosis result from a heightened immune response to a panel of inflammatory stimuli. In the case of sarcoidosis, the response to vimentin, a cytoskeletal protein, appears to play a role in pathology. Although sarcoidosis is typically diagnosed on the basis of subjective information, an in vivo skin assay, the Kveim test, has also proved useful.

Physicians perform the Kveim test using Kveim (Kv) reagent, a homogenized, heated suspension of sarcoidosis spleen tissue. The Kv reagent stimulates the formation of granulomas, but the mechanism behind this process is not well understood. However, the resulting skin reaction has been clinically validated for the diagnosis of sarcoidosis. After patients are diagnosed with sarcoidosis, they are treated, sometimes with immunosuppressive therapies.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Although clinicians do not completely understand the Kv reaction, they have noted that peripheral blood mononuclear cells (PBMCs) from human immunodeficiency virus (HIV)-positive patients who do not have sarcoidosis also respond to the Kv reagent by producing pro-inflammatory cytokines, suggesting that HIV and sarcoidosis may be related via the persistent secretion of pro-inflammatory cytokines.

Christian Eberhardt, MD, of the Imperial College London in the U.K., and colleagues investigated the Kv response in patients with newly diagnosed pulmonary sarcoidosis and published their results on Jan. 23, 2017, in PLOS ONE.1 The researchers first stimulated PBMCs from patients with sarcoidosis, as well as healthy volunteers with both sarcoidosis Kv (sKv) and healthy control spleen prepared in a manner similar to Kveim (cKv). The mean IFN-ɣ concentration was significantly higher in the cell culture supernatant from patients with active pulmonary sarcoidosis stimulated with sKv relative to cKv. In addition, the investigators found that, when they stimulated PBMCs from sarcoidosis patients with Kv reagent, they were able to induce a specific pro-inflammatory cytokine response (increased IFN-ɣ and TNF-α) that was not seen in PBMCs from healthy volunteers who were stimulated with Kv reagent.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The researchers then extracted proteins from eight historical diagnostically in vivo validated Kv (vKv) samples, six sKv samples and seven cKv samples, and used proteomic approaches to identify 74 sarcoidosis tissue-specific proteins—three of which were in higher abundance in sarcoidosis spleen relative to control spleen: vimentin, tubulin and alpha-actinin-4. In particular, the investigators identified high levels of vimentin in three historical vKv samples and one prepared sKv sample. Moreover, immunohistochemical staining of spleen tissue revealed that vimentin was localized to tissue granulomas of sarcoidosis, but not healthy spleens.

When the team stimulated sarcoidosis PBMC with these three candidate proteins, they found that vimentin—but not tubulin or alpha-actinin-4—could stimulate a strong IFN-ɣ and TNF-α response similar to that observed with stimulation by Kv. Likewise, vimectin did not stimulate production of IL-1 or IL-6. The investigators hypothesized that vimentin acts as a mycobacterial-derived antigenic peptide to upregulate the cytokine responses from sarcoidosis PBMCs.

Page: 1 2 | Single Page
Share: 

Filed under:ConditionsRheumatoid Arthritis Tagged with:Kveim reagentperipheral blood mononuclear cellsRheumatoid Arthritis (RA)Sarcoidosis

Related Articles

    Sarcoidosis in the Spotlight: Screening, Treatment & More Insights into Sarcoidosis

    June 1, 2021

    An expert discussed the screening and treatment of sarcoidosis and drug-induced sarcoidosis-like reactions during the 2021 ACR State-of-the-Art Clinical Symposium.

    Interferon Score Predicts AI-CTDs

    November 18, 2018

    People with autoimmune connective tissue diseases produce antibodies against nuclear antigens up to 10 years before they develop clinical features. Anti-nuclear antibodies (ANAs) are also very common, and a small percentage of ANA-positive patients progress to clinical autoimmunity. The question: Is there a reliable way to screen at-risk patients before they develop active autoimmunity and…

    Case Report: Sarcoidosis in Patient with History of IgG4-Related Disease

    September 14, 2021

    Sarcoidosis and IgG4-related disease (IgG4-RD) are both immune-mediated, often multi-organ, diseases of uncertain etiology capable of presenting with diverse clinical manifestations. Many clinical features are common to both conditions, including hypergammaglobulinemia, the ability to form inflammatory masses and involvement of the lymph nodes, lacrimal glands, salivary glands, meninges and lungs. Although imaging modalities, such as…

    Fellow’s Forum Case Report: New Sarcoidosis Cases in Patients Treated with Tumor Necrosis Factor–Alpha Inhibitors

    November 1, 2013

    Two patients with psoriatic arthritis treated with TNF-alpha inhibitor therapy develop the multisystem disease

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences